glp 1 agonist risks GLP-1 Agonists In Obesity The GLP-1 Agonists and Obesity:

Description

There is a strong recommendation not to combine DPP-4 inhibitors with GLP-1 receptor agonists, and DPP-4 inhibitor therapy should be discontinued when treatment is escalated with an injectable therapy at later stages with a GLP-1 receptor agonist (7072)

It should be noted that the GLP-1R + DVC/AP neurons project to the lateral parabrachial nucleus (PBN), which is in close proximity to the LC

Cure Reports Patient Perspectives on GLP-1s Costs, Side Effect and Life Style Successes In a new exclusive report, Insights from Patients on GLP-1RA Medications and the Future of Obesity Treatment , Cure unveils the results of a survey that sheds light on how patients navigate costs, side effects, and lifestyle changes while embracing the transformative potential of these medications for weight loss